Health Canada Consultation Survey for Bill C-17 Transparency Measures: open to May 25, 2015
Health Canada is requesting feedback from healthcare professionals, patients/family, researchers, pharmacists, data managers, and the general public regarding how therapeutic product information is disseminated as part of Bill C-17.
Bill C-17 introduced new transparency measures for therapeutic products, including:
- an obligation on therapeutic product authorization holders to make required information about their clinical trials publicly available on a website;
- an obligation on the Minister of Health to make publicly available all orders issued with respect to therapeutic products and positive and negative regulatory decisions; and,
- an authority for the Minister of Health to disclose confidential business information in certain circumstances.